{
    "organizations": [],
    "uuid": "94e4669943164d6c3827bf168b22d97fbdebf503",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-flexion-therapeutics-announces-ini/brief-flexion-therapeutics-announces-initial-data-from-clinical-trial-evaluating-repeat-administration-of-zilretta-idUSASB0C027",
    "ord_in_thread": 0,
    "title": "BRIEF-Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of Zilretta",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Flexion Therapeutics Inc:\n* FLEXION THERAPEUTICS ANNOUNCES INITIAL DATA FROM CLINICAL TRIAL EVALUATING REPEAT ADMINISTRATION OF ZILRETTAâ„¢ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)\n* FLEXION THERAPEUTICS - ZILRETTA FULL STUDY RESULTS EXPECTED IN Q3 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:38:00.000+02:00",
    "crawled": "2018-01-09T17:14:11.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "flexion",
        "therapeutic",
        "inc",
        "flexion",
        "therapeutic",
        "announces",
        "initial",
        "data",
        "clinical",
        "trial",
        "evaluating",
        "repeat",
        "administration",
        "triamcinolone",
        "acetonide",
        "injectable",
        "suspension",
        "flexion",
        "therapeutic",
        "zilretta",
        "full",
        "study",
        "result",
        "expected",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}